GlaxoSmithKline
GSK
$45.66
Share price
1.08%
Change (1 day)
24.14%
Change (1 year)
Categories
GlaxoSmithKline (GSK) - Total liabilities
Total liabilities on the balance sheet as of March 2024 : $57.22 B
According to GlaxoSmithKline's latest financial reports the company's total liabilities are $57.22 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
GlaxoSmithKline - Total liabilities on balance sheet (from 2001 to 2024)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $58.82 B | -3.03% |
| 2022-12-31 | $60.66 B | -22.2% |
| 2021-12-31 | $77.96 B | -4.06% |
| 2020-12-31 | $81.27 B | 1.05% |
| 2019-12-31 | $80.42 B | 16.49% |
| 2018-12-31 | $69.04 B | -3.42% |
| 2017-12-31 | $71.48 B | 6.97% |
| 2016-12-31 | $66.83 B | 1.19% |
| 2015-12-31 | $66.04 B | 18.78% |
| 2014-12-31 | $55.60 B | -1.65% |
| 2013-12-31 | $56.53 B | 0.67% |
| 2012-12-31 | $56.15 B | 12.24% |
| 2011-12-31 | $50.03 B | -0.23% |
| 2010-12-31 | $50.14 B | -3.52% |
| 2009-12-31 | $51.97 B | 14.12% |
| 2008-12-31 | $45.54 B | 8.57% |
| 2007-12-31 | $41.94 B | 34.31% |
| 2006-12-31 | $31.23 B | -7.42% |
| 2005-12-31 | $33.73 B | 6.56% |
| 2004-12-31 | $31.66 B | 14.27% |
| 2003-12-31 | $27.70 B | 47.85% |
| 2002-12-31 | $18.74 B | 10.1% |
| 2001-12-31 | $17.02 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $54.57 B | -4.62% | 🇨🇭 Switzerland |
 Pfizer PFE | $137.21 B | 139.78% | 🇺🇸 USA |
 Sanofi SNY | $57.61 B | 0.68% | 🇫🇷 France |
 Merck MRK | $69.04 B | 20.65% | 🇺🇸 USA |
 AstraZeneca AZN | $64.79 B | 13.23% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | $35.35 B | -38.22% | 🇮🇱 Israel |
 Dynavax Technologies
DVAX | $0.37 B | -99.34% | 🇺🇸 USA |